GHK-Cu

What it is

GHK-Cu (glycyl-histidyl-lysine copper) is a naturally occurring tripeptide complex that exists in human plasma at concentrations of approximately 200 ng/mL in young adults, declining to about 80 ng/mL by age 60. The molecule consists of the GHK tripeptide bound to a copper(II) ion in a 1:1 ratio. The copper coordination is essential to GHK’s biological activity — copper-free GHK has dramatically reduced effects.

GHK was first isolated from human plasma in 1973 by Loren Pickart, who observed that it stimulated growth and survival of liver cells in culture. Subsequent decades of research have characterized roles in skin remodeling, hair follicle biology, wound healing, and broader tissue regeneration. GHK-Cu has been extensively used in cosmetic formulations and in research applications, with growing interest in clinical compounded use for systemic effects.

The peptide is not FDA-approved as a pharmaceutical but has long-standing GRAS status for cosmetic use. The cosmetic applications dominate consumer awareness; the medical compounded applications are a smaller, more clinically focused use case.

Mechanism of action

GHK-Cu’s effects span multiple regenerative pathways:

• Collagen and extracellular matrix synthesis: stimulates fibroblast production of collagen (types I and III), elastin, glycosaminoglycans, and proteoglycans. This is the basis for skin remodeling effects and contributes to general connective tissue support.
• Wound healing acceleration: upregulates expression of multiple growth factors at wound sites, promotes fibroblast and keratinocyte migration, and enhances angiogenesis around healing tissue.
• Antioxidant effects: the copper component contributes to antioxidant defense by upregulating superoxide dismutase activity and other endogenous antioxidant systems. GHK-Cu can also directly bind reactive oxygen species.
• Anti-inflammatory effects: reduces pro-inflammatory cytokine production, suppresses neutrophil infiltration in inflamed tissue, and modulates the inflammatory phase of healing toward resolution.
• Hair follicle biology: extends the anagen (growth) phase of the hair cycle and stimulates dermal papilla cell proliferation, supporting hair density.
• Gene expression modulation: a 2010 microarray study by Pickart and colleagues found GHK-Cu modulated expression of over 4,000 human genes, with patterns suggesting broad effects on tissue regeneration, DNA repair, and stem cell biology.

Research findings

Skin remodeling and photoaging: multiple human trials with topical GHK-Cu formulations have demonstrated improvements in fine lines, skin density, hydration, and elasticity. Effect sizes are modest but real, comparable to other established cosmeceutical agents.

Wound healing: human studies in surgical wounds, burn injuries, and chronic ulcers have shown accelerated healing with topical or local GHK-Cu application. The peptide has long-standing clinical use in wound care in some practice settings.

Hair density: formulations combining GHK-Cu with other peptides have shown improvements in hair density and follicle thickness in androgenetic alopecia studies. Effect sizes are smaller than minoxidil or finasteride but with a much more favorable side effect profile.

Systemic injectable use: human research is limited. Practitioner experience supports utility in skin remodeling protocols and as adjunct in tendon recovery, but rigorous trial data is sparse.

How we use it at The Tide

We prescribe GHK-Cu in two distinct ways depending on the clinical goal:

Topical formulations: for facial skin remodeling protocols, post-procedure recovery (e.g., after microneedling, laser, or chemical peels), and selected wound healing applications. We use compounded preparations at concentrations of 0.05–0.2%, typically applied twice daily.

Subcutaneous injection: for systemic effects on skin density, connective tissue support, and as an adjunct in tendon recovery protocols. Standard dosing is 1–2 mg subcutaneously, 3–5 times per week, for 8–12 week cycles.

What good response looks like: topical users typically see improvements in skin texture and luminosity within 4–6 weeks, with continued improvement through 12 weeks. Subcutaneous users often report improvements in skin appearance, hair density, and recovery from training within 6–8 weeks.

We do not retail or sell specific cosmetic GHK-Cu products — that is the domain of the cosmetic industry. Our role is in clinical applications where compounded formulations and physician oversight are appropriate.

Side effects and contraindications

GHK-Cu has an excellent safety profile across decades of cosmetic and clinical use. The copper content at therapeutic doses is well below toxicity thresholds — typical injections deliver micrograms of copper compared to the 0.9 mg recommended daily intake.

• Mild skin irritation can occur with topical formulations, particularly at higher concentrations
• Rare allergic-type reactions to topical use, generally to formulation excipients rather than the peptide itself
• Mild injection site reactions with subcutaneous use
• The blue-green color of the copper-peptide complex can occasionally cause transient color tinting at injection sites

Contraindicated in:

• Wilson disease and other disorders of copper metabolism
• Documented copper allergy
• Active malignancy (theoretical concern given regenerative effects)
• Pregnancy and breastfeeding (absence of safety data)

What we don’t yet know

Optimal dosing for systemic effects from subcutaneous administration is largely empirical. Long-term effects of regular cyclical injectable use have not been formally characterized in humans. The mechanism by which GHK-Cu produces effects on tissues distant from the injection site (vs. purely local effects) is not fully understood. Comparative effectiveness against established treatments for skin aging, hair loss, and wound healing is not well documented in head-to-head studies. GHK-Cu represents one of the more established compounds in our toolkit — supported by extensive mechanistic understanding and decades of safety data — used as part of broader skin and connective tissue protocols.